Drs. Mark Gladwin and Jesus Tejero‘s R01 titled, “Antidote for inhaled CO poisoning based on mutationally engineered neuroglobin,” was competitively renewed with annual direct costs of $637,860 by the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI). This proposal was submitted in response to the competitive funding opportunity titled NIH Research Project Grant (Parent R01) under funding opportunity number PA-18-484.
Carbon monoxide poisoning results in an estimated 50,000 emergency department visits in the United States annually and is one of the leading causes of poisoning death. In this project, Drs. Gladwin and Tejero aim to develop a specific antidotal therapy that can be given in the field by paramedics that can remove carbon monoxide from red blood cells, tissues, and heart and brain mitochondria within minutes. The availability of an effective antidote for carbon monoxide has the potential to the dramatically change the current treatment and has the potential to substantially decrease death and disability caused from this common poisoning.